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Abstract
Background: Urinary stone disease is very common with an estimated prevalence among the general population
of 2–3%. Ureteric stones are associated with severe pain as they pass through the urinary tract and have significant
impact on patients’ quality of life due to the detrimental effect on their ability to work and need for hospitalisation.
Most ureteric stones can be expected to pass spontaneously with supportive care. However, between one-fifth and
one-third of cases require an intervention.
The two standard active intervention options are extracorporeal shockwave lithotripsy (ESWL) and ureteroscopic stone
retrieval. ESWL and ureteroscopy are effective in terms of stone clearance; however, they differ in terms of invasiveness,
anaesthetic requirement, treatment setting, complications, patient-reported outcomes (e.g. pain after intervention, time
off work) and cost. There is uncertainty around which is the most clinically effective in terms of stone clearance and the
true cost to the NHS and to society (in terms of impact on patient-reported health and economic burden).
The aim of this trial is to determine whether, in adults with ureteric stones, judged to require active intervention, ESWL
is not inferior and is more cost-effective compared to ureteroscopic treatment as the initial management option.
Methods: The TISU study is a pragmatic multicentre non-inferiority randomised controlled trial of ESWL as the first
treatment option compared with direct progression to ureteroscopic treatment for ureteric stones.
Patients aged over 16 years with a ureteric stone confirmed by non-contrast computed tomography of the kidney,
ureter and bladder (CTKUB) will be randomised to either ESWL or ureteroscopy. The primary clinical outcome is
resolution of the stone episode (no further intervention required to facilitate stone clearance) up to six months from
randomisation. The primary economic outcome is the incremental cost per quality-adjusted life years (QALYs) gained at
six months from randomisation.
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Discussion: Determining whether ESWL is not inferior clinically and is cost-effective compared to ureteroscopic
treatment as the initial management in adults with ureteric stones who are judged to require active treatment is
relevant not only to patients and clinicians but also to healthcare providers, both in the UK and globally.
Trial registration: ISRCTN registry, ISRCTN92289221. Registered on 21 February 2013.
Keywords: Ureteric stone, ESWL, Ureteroscopy
Background
Urinary stone disease is very common with an estimated
prevalence among the general population of 2–3% (1.8
million people in the UK) with males forming stones three
times as often as females [1]. Urinary stones often recur
and the lifetime recurrence rate is approximately 50% [2].
The interval between recurrences is variable, with ap-
proximately 10% within one year, 35% within five years
and 50% within ten years [3]. The increased incidence of
urinary stones in the industrialised world is associated
with improved standards of living (mainly due to the high
dietary intake of proteins and minerals) and there is also
an association with ethnicity and region of residence [4].
Urinary tract stones, and ureteric stones in particular, are
associated with severe pain as they pass through the
urinary tract and can have a significant impact on patients’
quality of life due to the detrimental effect on their ability
to work and the need for hospitalisation.
Urinary stones are a major burden on the NHS result-
ing in over 84,323 finished consultant episodes and over
97,558 bed-days in England in 2011–2012 [5]. When
urinary stones move from the kidney into the ureter
(tube connecting the kidney to the bladder), they cause
severe debilitating pain (ureteric colic) that causes a
large transient impairment of quality of life and leads to
substantial calls on health service resources. Ureteric
colic is the most common cause of emergency admission
to Urology departments in the UK [5] and since it pre-
dominantly affects younger people (aged 16–55 years) is
a common cause of time off work. The aim of treatment
for ureteric stones is the immediate relief of symptoms,
decompression of the urinary tract and the achievement
of clinically complete stone clearance.
Most ureteric stones can be expected to pass spontan-
eously with supportive care (painkillers and fluids), so-
called conservative management. Between one-fifth and
one-third of cases require an active intervention (stone
removal) because of failure to pass the stone, continuing
pain, infection or obstruction to urine drainage. The two
standard active intervention options are extracorporeal
shockwave lithotripsy (ESWL) and ureteroscopic stone
retrieval. While both ESWL and ureteroscopy appear to
be effective in terms of stone clearance they differ in
terms of invasiveness, anaesthetic requirement, treat-
ment setting, the number of procedures required to clear
the stone, complications, patient-reported outcomes (such
as severity and duration of pain after intervention, time
off work and bothersome urinary symptoms) and cost.
There is uncertainty around which is the most clinically
effective in terms of stone clearance and the true cost to
the NHS and to society (in terms of impact on patient-
reported health and economic burden).
A joint clinical guideline on the management of ureteric
stones by the European Association of Urology and the
American Urological Association [6] estimates that 68% of
stones ≤ 5 mm and 47% of stones 5–10 mm in size can be
expected to pass spontaneously and concluded that the
majority of these stones pass within four to six weeks of
presentation. Stones in the distal ureter pass more readily
than stones located more proximally. Consequently,
patients with favourable features and with smaller sized
stones in the lower ureter are initially treated conserva-
tively. Immediate active intervention occurs in those
patients with larger stones and unfavourable features who
are deemed clinically to be unsuitable for conservative
treatment. Those who fail standard conservative care or
who subsequently develop complications also undergo
later active treatment. This can be ESWL, preliminary
ureteric stenting with later stone removal, ureteroscopy
with stone retrieval or destruction (in situ lithotripsy) or
percutaneous nephrostomy insertion and later stone
removal. ESWL and ureteroscopic treatment require
expensive equipment and urological expertise. Both have
been shown to be options that are safe and effective in a
number of studies. In clinical practice, urologists tend to
favour ureteroscopy over ESWL particularly for mid and
lower ureteric stones due to perceived higher rate of
clinical stone clearance [7].
A Cochrane systematic review (2007) [8] comparing
the effectiveness of ESWL with ureteroscopic manage-
ment of ureteric stones identified seven randomised con-
trolled trials (RCTs) involving a total of 732 participants.
The results of this review suggest stone-free rates were
lower in the ESWL group (RR (relative risk) = 0.83, 95%
confidence interval [CI] = 0.70–0.98); reflecting this
retreatment, rates for ESWL were higher (RR = 2.78, 95%
CI = 0.53–14.71) but these findings are associated with
much uncertainty. Complications were less frequent after
ESWL (RR = 0.44, 95% CI = 0.21–0.92) and this option
was associated with a shorter hospital stay (mean
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difference = 2.10 days, 95% CI = – 2.55 – – 1.64 days).
The review concluded that ureteroscopic treatment of
stones was associated with a higher stone free rate but
a higher morbidity (complication rate) and a longer
hospital stay. However, the overall quality of the studies
was poor and inclusion criteria were strict in each study,
limiting both the generalisability and applicability of the
review findings. There was limited evidence on which to
judge the comparative effectiveness in clinically important
prognostic subgroups for example location of stones in
the ureter. None of the studies reported on health-related
quality of life and only one reported a cost-effectiveness
outcome. The review authors recommended that a large-
scale multicentre RCT was needed to adequately address
the effectiveness and cost-effectiveness of ureteroscopy
versus ESWL. A 2011 update of the Cochrane review [9]
has included two further studies but these have not altered
the previous conclusions.
The European Association of Urology and the Ameri-
can Urological Association (EAU-AUA) Clinical Guide-
line Panel on the management of ureteric stones also
conducted a review and meta-analysis reporting clinical
outcomes and complications following treatment of ur-
eteric stones with ESWL or ureteroscopy, including data
from non-randomised comparisons and case series [6].
Pre-defined outcome measures were stone-free rate and
number of additional procedures required. The results
were stratified according to stone location in the ureter
(proximal, mid, distal) and stone diameter (≤ 10 mm, >
10 mm). All forms of ESWL were analysed as a single
treatment modality in the meta-analysis. The Panel con-
cluded that the main advantage of ureteroscopy is a
higher stone-free rate with a single procedure, but with
a higher complication rate. However, the evidence was
insufficient for the Panel to recommend between ESWL
and ureteroscopy and concluded that for patients requir-
ing active stone removal, either treatment modality is
acceptable as first-line options. For the individual patient,
the choice is often determined by a number of factors
including the availability of resources, preference of the
treating urologist, and preference of the patient. The
review highlighted design and reporting deficiencies from
available studies, including poor definition of stone size,
inconsistent reporting of outcomes and lack of randomisa-
tion. One of the main recommendations of the Panel was
the need to conduct RCTs comparing the clinical and
cost-effectiveness of ESWL and ureteroscopy.
In response to the research questions raised by these
evidence summaries, the TISU trial will provide the
high-quality evidence, from a large pragmatic RCT, on
the relative effectiveness, and cost-effectiveness, of
ESWL and ureteroscopy, that will inform patients, clini-
cians and policy makers on the optimal choice of inter-
vention for ureteric stones.
The aim of this trial is to determine whether in adults
with ureteric stones judged to require active treatment,
ESWL is not inferior, clinically, and is more cost-
effective compared to ureteroscopic treatment as the ini-
tial management option.
The hypothesis being tested is that the outcome in pa-
tients receiving ESWL as their first treatment option is
not inferior to outcome in patients receiving direct ure-
teroscopic retrieval. The clinical and cost-effectiveness
will be determined with respect to:
i. Resolution of stone episode (stone clearance),
defined as no further intervention required to
facilitate stone passage;
ii. Incremental cost per quality-adjusted life years
(QALYs);
iii. Participant-reported health outcomes; and
iv. Disease or treatment-related harms up to six months
post randomisation.
Methods and design
A pragmatic, multicentre, non-inferiority RCT of ESWL
as the first treatment option compared with direct pro-
gression to ureteroscopic treatment for ureteric stones.
The trial will be conducted in secondary care units with
a high volume of ureteric stones across the UK and at
sites that have a fixed lithotripter. Figure 1 summarises
the trial design.
Inclusion and exclusion criteria
Inclusion criteria
 Presence of stone confirmed by CTKUB
 Patients with a ureteric stone requiring removal
 Adults aged ≥ 16 years
 Single ureteric stone requiring treatment
 Suitable for either ESWL or ureteroscopic treatment
 Capable of giving written informed consent, which
includes adherence with the requirements of the
trial
Exclusion criteria
 Pregnancy
 Stones not confirmed by CTKUB
 Bilateral ureteric stones
 Patients with abnormal urinary tract anatomy (such
as horseshoe kidney or ileal conduit)
 Patients unable to understand or complete trial
documentation
Trial interventions
Two interventions will be evaluated: (1) ESWL and (2)
ureteroscopy.
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Identification and enrolment of potential participants
Local procedures at participating hospitals are different;
the timing and mode of approach to patients and the
consent process will vary to accommodate both the vari-
ability at the sites and needs of the patient. As standard
practice, clinicians or delegated personnel will assess
patients presenting with suspected ureteric calculi. A log
will be taken of all patients assessed in order to docu-
ment the reasons for non-inclusion in the study (e.g.
reason they were ineligible or declined to participate) to
inform the CONSORT diagram. Brief details of poten-
tially eligible patients will be recorded in the screening
logs at each site (these will be an aid to monitoring
potential participant inclusion). Following adequate pain
relief and confirmation of ureteric calculi by CTKUB,
eligible patients (according to the inclusion and exclu-
sion criteria) will be provided a patient information
leaflet. The information leaflet will be given to each po-
tential participant to inform them of the benefits and
known drawbacks of all aspects of this trial. The PIL
explains that the trial is investigating the use of either
ESWL or ureteroscopic treatment as the first treatment
option for symptomatic ureteric stones that require an
active intervention. Each patient will have the opportun-
ity to discuss the study with the local clinical team.
Patients may make a decision to participate, during a
Fig. 1 Flow diagram. Randomised controlled trial comparing extracorporeal shockwave lithotripsy (ESWL) with ureteroscopic retrieval as first
treatment options for urinary stones
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consultation with the local clinical team during a visit to
hospital (e.g. when they attend a clinic appointment or
while a patient in hospital for their initial stone episode)
or alternatively at home. If the patient agrees to be con-
tacted at home, he/she may receive a telephone call from
the local Research Nurse to discuss any queries. Signed
informed consent forms will be obtained from the
participants in all centres. Participants who cannot give
informed consent (e.g. due to incapacity) will be not be
eligible for participation. The participant’s permission
will be sought to inform their general practitioner that
they are taking part in this trial. Patients who decide to
participate following telephone counselling can either
send their completed documents (consent form and
baseline questionnaire) through the post to the local
team at their treating hospital or bring it with them if
they are returning to hospital for another consultation
or treatment. Participants will be randomised to one of
the two treatment groups following consent, completion
and receipt of baseline questionnaire.
Randomisation and allocation
Eligible and consenting participants will be randomised to
one of the two intervention groups using the telephone
Interactive Voice Response (IVR) randomisation applica-
tion or via the web-based application - both hosted by the
Centre for Healthcare Randomised Trials (CHaRT),
Health Services Research Unit (HSRU) in Aberdeen,
which is a fully registered, Clinical Trials Unit (CTU) with
the UK Clinical Research Collaboration (UKCRC).
Randomisation will be minimised by centre, stone size
(≤ 10 mm or > 10 mm, as measured by the maximum
stone diameter on CTKUB) and location of the stone in
either the upper, mid or lower ureter (as defined in the
EAU/AUA Guidelines).
Trial procedures
Participants will complete a total of five questionnaires.
They will be asked to complete the EQ-5D-3L, SF-12,
pain score (Numerical Rating Scales [NRS]) and use of
analgesics at baseline in the hospital when recruited to
the trial. Participants will be asked to complete the EQ-
5D-3L, pain score and use of analgesics questions (self-
completed) at their allocated intervention visit to sec-
ondary care immediately before receiving their interven-
tions. At one week post intervention they will be asked
to complete the pain score and use of analgesics ques-
tions by self-completed questionnaire. At eight weeks
and then six months post randomisation, participants
will be asked to complete a questionnaire to measure
the EQ-5D-3L, SF-12, pain score (NRS) (eight weeks
only), use of analgesics, complications, additional inter-
ventions received and acceptability of the received pro-
cedure. In addition, at six months post randomisation,
participants will be asked to complete questions relating
to their primary and secondary care use.
Four case report forms (CRFs) will be completed by
the research team at the recruiting site. A baseline CRF
will be completed at randomisation of the patient. A
treatment CRF will be completed following the rando-
mised intervention. The CRFs at eight weeks and six
months post randomisation will be completed and en-
tered at site by the centre coordinators at the recruiting
centres. They will collect additional interventions
received and reasons for those, reasons why they might
not have received their allocated intervention, complica-
tions and date of stone passage. Additional hospital visits
will be recorded on a supplementary CRF.
Subject withdrawal
Participants will remain on the trial unless they chose to
withdraw consent or if they are unable to continue for a
clinical reason. If a participant withdraws consent, par-
ticipant questionnaires will not be collected; however,
permission will be sought for the research team to
continue to collect outcome data from their healthcare
records (via the CRFs). All other changes in status with
the exception of formal withdrawal of consent will mean
the participant is still followed up for all study outcomes
wherever possible.
Outcome measures
The study has a primary clinical and a primary economic
outcome.
Primary outcomes
Clinical Resolution of stone episode defined as no fur-
ther intervention required to facilitate stone clearance
up to six months from randomisation.
Economic Incremental cost per QALYs gained at
six months from randomisation. QALYs are based on
the responses to the EQ-5D-3L.
Secondary outcomes
Patient-reported:
 Health state (EQ-5D-3L) at pre intervention, at one
week post intervention, at eight weeks and at
six months post randomisation.
 Pain intensity at pre intervention, at one week post
intervention and at eight weeks post randomisation.
 Functional generic health and wellbeing (SF-12), at
eight weeks and at six months post randomisation.
 Analgesic use at pre intervention, at one week post
intervention and at eight weeks post randomisation.
 Acceptability of received procedure at eight weeks
post randomisation.
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Clinical:
 Further interventions received up to six months post
randomisation.
 Complications up to six months post randomisation.
Economic
 NHS primary and secondary care use and costs up
to six months.
 Patient costs up to six months.
 Incremental cost per surgical interventions averted.
Timing and measures used to assess outcome
Table 1 shows the schedule of outcome assessment and
data collection.
The EQ-5D-3L is used to measure health state today.
The pain intensity measure is a NRS [10] using the
question ‘Please rate the level of pain that you are ex-
periencing today?’ plus at one week post intervention
only ‘Please rate the worst level of pain that you have ex-
perienced since your trial treatment?’ The NRS is a seg-
mented numeric scale. The respondent selects a whole
number (0–10 integers) that best reflects the intensity of
pain. This scale is a horizontal line. The scale is an-
chored by terms describing pain severity extremes 0 (no
pain) to 10 (worst imaginable pain). In addition, partici-
pants are asked ‘During the last 7 days have you had
pain related to your ureteric stone?’ Yes or No.
The SF-12 measures functional health and wellbeing
over the past four weeks summarised in the Physical
Component Summary (PCS) and Mental Component
Summary (MCS) scores.
Analgesic use is measured with the question ‘How
many days out of the last seven have you used pain relief
medication?’
The acceptability of the procedure is measured using
the question ‘Would you recommend the treatment to a
friend?’ In addition, the participant is asked to rate the
importance of a list of attributes of treatment: duration
of hospital stay; need for further treatment; no complica-
tions; pain after treatment; delay in resuming normal
daily activities; time off work where 1 = least important
and 6 =most important.
Safety
Timing and recording of safety parameters
The TISU trial involves procedures for treating ureteric
stone which are well established in clinical practice.
Adverse effects may occur during or after any type of
surgery.
Procedures for recording and reporting adverse events (AEs)
and serious adverse events (SAEs)
Assessing and recording AEs and SAEs Non-serious
events will not be collected or reported. Planned hospital
visits for conditions other than those associated with the
ureteric stone will not be collected or reported. Hospital
visits (planned or unplanned) associated with further
interventions to facilitate ureteric stone clearance will be
recorded as an outcome measure but will not be
reported as SAEs.
Within TISU, ‘relatedness’ is defined as an event that
occurs as a result of a procedure required by the proto-
col, whether this procedure is the specific intervention
under investigation and whether it would have been
administered outside the study as normal care.
Any SAEs related to the participants’ ureteric stone
treatments that are not further interventions to facilitate
stone clearance (e.g. if a participant is admitted to
hospital for treatment of infection) will be recorded on
the SAE form. In addition, all deaths for any cause
(related or otherwise) will be recorded on the SAE form.
The trial office, with the assistance of the CI, will pre-
pare a summary of all serious adverse reactions every six
months. These will be distributed to the participating
investigators, the Co-Sponsors, the trial steering com-
mittee and the DMC.
Table 1 Source and timing of outcome measures
Outcome measures Source Timing
Intervention Post randomisation
Recruitment Pre 1 week post 8 weeks 6 months
Additional interventions received CRF & PQ ✓ ✓
Pain (NRS) PQ ✓ ✓ ✓ ✓
Health status EQ5D PQ ✓ ✓ ✓ ✓ ✓
Health profile SF-12 PQ ✓ ✓ ✓
Use of analgesics PQ ✓ ✓ ✓ ✓
Complications CRF ✓ ✓
NHS primary and secondary healthcare use PQ & CRF ✓
Participant costs PQ ✓
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In addition, all suspected serious adverse reactions will
be collated annually and submitted to the REC in ac-
cordance with the guidance on annual safety reporting.
The DMC will regularly assess the safety data collected
for the trial and will have ability to advise that the trial is
temporarily or permanently halted based on safety con-
cerns according to the criteria defined in their charter.
Sample size
The original sample size calculations reflect that the
TISU trial is a non-inferiority design. Published litera-
ture [1, 8, 9] suggests the proportion stone free without
further intervention up to six months in the uretero-
scopy arm will be about 0.75 (P1) and in the ESWL arm
about 0.65 (P2). The margin of inferiority deemed
acceptable is 0.20 so that P2-P1 > − 0.20. The sample size
was estimated using simulations, designed for this pur-
pose, run in Stata. The power of a non-inferiority trial
can be considered as the probability that the lower
bound of the estimated 95% CI around the difference
between trial proportions excludes the margin of non-
inferiority. Simulating 1000s of trials of fixed sizes with
the parameters P1 and P2 as above indicates that a trial
of 450 per arm is required for the lower bound of the
estimated 95% CI to exclude − 20% with 90% power.
Adjustment for potential 10% drop-out inflates the trial
to 1000 in total. A trial of this size would have above
90% power to test superiority on secondary outcomes of
an effect size of one-quarter of a standard deviation.
Following poor recruitment and interim data analysis
of 267 participants, the sample size was amended from
1000 downwards to 750. The amendment has been rati-
fied by the trial oversight committees and the sponsor
and the funder. Recruitment projections showed us that
the original sample size of 1000 was unachievable in a
realistic timeframe despite measures implemented to im-
prove recruitment. We agreed with the funder an exten-
sion of 18 months to reach a revised sample size of 750.
Our original sample size of 1000 included a 15% uplift
from 850 to perform the primary analysis under a suit-
ably defined per-protocol analysis. A per-protocol ana-
lysis, in the special context of a non-inferiority design, is
often seen as the more conservative approach than the
conventional intention-to-treat (ITT) analysis.
This per-protocol analysis would have excluded any
participants that crossed over from their randomly allo-
cated treatment to the other and would have excluded
any participant whose stone cleared before their ran-
domly allocated treatment was initiated. However, the
view of the HTA Board, which has since been confirmed
by the TISU independent Data Monitoring Committee
(iDMC), is that the ITT approach should take primacy
over this per-protocol approach, to better reflect that the
purpose of this pragmatic effectiveness trial is to
compare the policy of initiating one or other of these
treatment options and not to focus on the actual com-
parative performance of the treatment options themselves.
The per-protocol approach will still be used as a support-
ing analysis. This is also a rare context in which there is
no missing outcome data, since we are sure that we will
have identified any further interventions to facilitate stone
clearance in the six months postoperatively; hence, we can
say with certainty for each individual randomised whether
the original operation cleared the stone.
Based on the 267 participants with mature outcome
data as of 16 February 2016, the iDMC observed that all
the assumptions behind the power calculation remain
plausible. Given that we are now committed to the ITT
approach rather than the per-protocol approach (and
under the original design of assuming the proportion
stone free in ESWL arm would be 65% and 75% in the
ureteroscopy arm) the achievable sample size of 750 will
give 85% power. If we recruit 750, under the assumption
of 15% crossover and stone clearance, before initiation
of the randomly allocated intervention, then the per-
protocol analysis of 638 individuals will still retain ~ 80%
power under the same assumptions as above.
Statistical analysis
Treatment groups will be described at baseline and
follow-up using means (with standard deviations), me-
dians (with inter-quartile ranges) and numbers (with
percentages) where relevant. Primary and secondary out-
comes will be compared using generalised linear models,
with adjustment for participant baseline and design
covariates, (stone ≤ 10 mm and stone > 10 mm; location
in ureter: upper, mid or lower; age; and gender). The
measures and timings of outcomes are described in the
‘Outcome measures’ section and Table 1.
Statistical analysis will be per-protocol and ITT (as
is recommended for non-inferiority trials) with results
displayed as estimates and 95% CIs derived from
appropriate generalised linear models. CIs around
observed differences will then be compared to the
pre-specified non-inferiority margin. Subgroup ana-
lyses (appropriately analysed by testing treatment by
subgroup interaction) will explore the possible effect
modification by type and location of stone and gen-
der; all using stricter levels of statistical significance
(p < 0.01, 99% CIs).
All analyses will follow a carefully documented Statis-
tical Analysis Plan (SAP). The SAP will be available to
both the Trial Steering Committee (TSC) and the iDMC
members should they wish to review and comment on
the document. A single main analysis will be performed
at the end of the trial when all follow-up has been
completed.
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Economic evaluation
Economic evaluation will be an integral part of the
study. Resource use and costs will be estimated for each
participant. The evaluation will consider the costs of the
care pathways that patients receive. Resource data col-
lected will include the costs of the interventions, ESWL
and ureteroscopy, and simultaneous and consequent use
of primary and secondary NHS services (including
additional interventions received) by participants. Per-
sonal costs, such as purchase of medications, particularly
analgesics, time and travel, will also be estimated. The
perspective of the study will be societal as it will include
both the NHS costs as well as that of the participants.
Collection of data
Primary and secondary care resource use will be col-
lected via the CRFs and participant questionnaires. Unit
costs will be based on routine sources (e.g. Reference
Costs or study specific estimates). QALYs will be based
on the responses to the EQ-5D-3L.
Participant costs
Participant costs will include self-purchased healthcare
such as prescription costs and over-the-counter medica-
tions, particularly analgesics.
NHS health service resource use
Use of secondary care services following the treatment
period will be collected using participant questionnaires
and CRFs. Information on outpatient visits, readmissions
relating to the use and consequences of the interven-
tions being compared will be recorded. Use of primary
care services such as prescription medications, contacts
with primary care practitioners, e.g. GPs and practice
nurses, will be collected via the ‘health care utilisation
questions’ administered at the six-month follow-up.
Cost-effectiveness
The cost-effectiveness will be measured in terms of costs
of the treatment care pathways and QALYs at six
months. QALYs will be estimated by transforming the
EQ-5D-3L scores (collected at baseline, eight weeks and
six months post randomisation) into utility values using
standard algorithms [11]. The results will be presented
as point estimates of mean costs, QALYs and incremen-
tal cost per QALY of each treatment care pathway.
Measures of variance for these outcomes are likely to
involve bootstrapping estimates of costs and incremental
QALYs. Incremental cost-effectiveness data will be pre-
sented in terms of cost-effectiveness acceptability curves
(CEACs). Forms of uncertainty, e.g. concerning the unit
cost of resources from the different centres, will be
addressed using standard deterministic sensitivity
analysis. Sensitivity analysis will also be used to explore
the impact of statistical imprecision and other forms of
uncertainty. Where feasible the results of the sensitivity
analyses will also be presented as CEACs.
Discussion
The TISU trial is a large, multicentre, pragmatic RCT to
determine the clinical and cost-effectiveness of a care
pathway that starts with ESWL compared to a care path-
way that starts with ureteroscopic treatment, for people
who have a stone in the ureter that requires an active
intervention. Clinical and cost-effectiveness is deter-
mined with respect to: (1) resolution of stone episode;
(2) incremental cost per QALYs; (3) participant-reported
health outcomes; and (4) disease or treatment-related
harms up to six months post randomisation.
The trial has been scored using the PRECIS-2 wheel
[12] (see Fig. 2: Diagram 1).
It is not possible to blind the TISU trial participants or
clinicians to their allocated initial treatments or any fur-
ther treatments. Lack of blinding may increase threats to
the internal validity, such as systematic differences in
withdrawal/follow-up, in care provided, in outcome
observation, measurement and assessment. In the
context of the TISU trial where we are evaluating the ef-
fectiveness of a care pathway that starts with concealed
random allocation to the initial treatment for a symp-
tomatic condition, we do not think lack of blinding is a
major threat to internal validity. The primary outcome is
‘Further interventions to resolve the stone episode up to
six months post randomisation’. The outcome is deter-
mined via CRF of interventions, collected and collated
by research nurses at sites. Standard care guidelines
guide treatment decisions and we would not expect
clinicians to withhold further interventions judged
necessary to facilitate resolution of the stone episode or
to withhold treatments for complications over the six
months after allocation.
One of the main continuing challenges of the TISU
trial is identification and recruitment of participants.
The care pathway for ureteric stone patients can be
complicated and many patients present to secondary
care through Accident and Emergency departments, out
of normal hours and are missed by research staff at site.
To overcome this issue, many sites are running stone
management clinics involving research staff to help iden-
tify participants. In other instances, the radiographer at
the participating sites is providing researchers with a list
of patients that have a single ureteric stone identified by
CTKUB. This has helped to ensure that potential
patients are not missed.
In addition, feedback from screening logs, qualitative
sub-study TISU Qual and discussions with sites have
indicated that study recruitment has been affected by
patients and clinicians having a preference for one
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treatment over the other. This is being investigated fur-
ther to understand the reasons for these preferences and
whether measures can be put in place to place them in
equipoise when considering the study. The impact of
this will be discussed in the full report.
Our previous experience with this patient population
has shown that response rates to participant question-
naires tend to be low (49% at 12-week questionnaire
follow-up as demonstrated in the SUSPEND trial,
August 2015). In anticipation of this, strategies to ensure
a better response rate were implemented at the start of
TISU. One of these approaches was to provide partici-
pants with the choice of how they would prefer to re-
ceive questionnaires either by post or via email. The
response rate to study questionnaires at six months has
always been low and we have observed a slow decrease
in the rate. The current rate is 65% completion at six-
month time-point. The overwhelming evidence from a
recent review of strategies to improve retention in a
clinical trial supports the use of monetary incentives in
improving response rates [13]. Based on this, we there-
fore plan to include a monetary incentive (unconditional
Fig. 3 Schedule of enrolment, interventions and assessments
Fig. 2 PRECIS-2 wheel for the TISU trial
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£10 gift voucher for high street stores) with the partici-
pant’s six-month questionnaire to try and improve
response rates. Again, the impact of this measure will be
discussed in the full trial report.
Other than the problems mentioned there have been no
other issues conducting the TISU trial. We have used the
recruitment experience on TISU to advise researchers
conducting similar trials encouraging them to consider
the practicalities of identifying and recruiting patients.
Trial status
The first participant was recruited in July 2013 and the
trial is closed to recruitment and is in follow-up.
Additional file
Additional file 1: Figure 3 SPIRIT 2013 Checklist: Recommended items to
address in a clinical trial protocol and related documents. (DOC 120 kb)
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